Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (32)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Germann, N.
Right arrow Articles by Misset, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Germann, N.
Right arrow Articles by Misset, J. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 10:351-354, 1999
© 1999 European Society for Medical Oncology

brief-report

Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients

N. Germann1, S. Brienza1, M. Rotarski1, J. F. Emile2, M. Di Palma1, M. Musset1, M. Reynes2, P. Soulie1, E. Cvitkovic1 and J. L. Misset1,

1Fédération des Maladies Sanguines, Immunitaires el Tumorales Villejuif, France
2Départemenl d'Analomopalhologie, Höpital Paid Brousse Villejuif, France

Prof. J. L. Misset, Fédération des Services des Maladies Sanguines et Tumorales, Höpital Paul Brousse, 14 Avenue Paul Vaillant Couturier, 94804 Villejuif, France

Background: Many patients with advanced NHL ultimately relapse and require salvage treatment. Oxaliplatin, a diamino-cyclohexane (DACH) platinum, has shown a differential spectrum of cytotoxicity with cisplatin, with activity in primary or secondary cisplatin-resistant solid tumors (colon and ovarian cancer). We report the tolerance/activity of this platinum derivate in previously-treated NHL patients.

Patients and methods: From July 1988 to February 1994, 22 patients (11 men, 11 women) with recurrent NHL received single-agent oxaliplatin (100–130 mg/m2 i.v. over two hours with antiemetic premedication, q three weeks). All had been previously treated (median number of prior chemotherapy regimens 2, range 1–7) ≥ 1 alkylating agent: 22 patients, anthracy-clines: 18 patients, cisplatin: four patients, and radiation: 11 patients. Fourteen patients (63%) had progessive disease as best response to their last chemotherapy, and were considered treatment-refractory. All histologies were centrally reviewed in accord with the R.E.A.L. Classification; they were: eight follicular, five MCL, three diffuse large cell, two MALT, one lymphoplasmocytoid, and three other.

Results: A total of 144 cycles were administered for a median number of 6 (range 1–30) per patient. The objective response rate was 40% (95% CI: 21–64), including one CR (MCL) and eight PRs (four follicular, two MCL, two MALT). The median response duration was 27 months (range 5–44). Treatment-related toxicity was limited to grade 1–2 nausea/vomiting and reversible grade 1–2 peripheral neuropathy in most of the patients.

Conclusion: Oxaliplatin is an active agent in relapsed/refractory NHL, including the MCL type. Its safety profile makes this agent a good candidate for the development of combined salvage regimens. Further phase II studies are needed to confirm these preliminary results.

monotherapy, non-Hodgkin's lymphoma, oxaliplatin, salvage therapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
M. Raderer, S. Wohrer, R. Bartsch, G. Prager, J. Drach, M. Hejna, A. Gaiger, K. Turetschek, U. Jaeger, B. Streubel, et al.
Phase II Study of Oxaliplatin for Treatment of Patients With Mucosa-Associated Lymphoid Tissue Lymphoma
J. Clin. Oncol., November 20, 2005; 23(33): 8442 - 8446.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Pless, K. Belhadj, H. D. Menssen, W. Kern, B. Coiffier, J. Wolf, R. Herrmann, E. Thiel, D. Bootle, I. Sklenar, et al.
Clinical Efficacy, Tolerability, and Safety of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma: Results from a Phase II Multicenter Study
Clin. Cancer Res., February 15, 2004; 10(4): 1299 - 1305.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Mavroudis, P. Pappas, C. Kouroussis, S. Kakolyris, S. Agelaki, K. Kalbakis, N. Androulakis, J. Souglakos, N. Vardakis, M. Nikolaidou, et al.
A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors
Ann. Onc., February 1, 2003; 14(2): 304 - 312.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.